Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer

PURPOSE: Persistent androgen receptor (AR) transcriptional activity is clinically evident in castration-resistant prostate cancer (CRPC). Therefore, AR remains as a viable therapeutic target for CRPC. All current hormonal therapies target the C-terminus ligand-binding domain (LBD) of AR. By using EP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Yang, Yu Chi, Banuelos, C Adriana, Mawji, Nasrin R., Wang, Jun, Kato, Minoru, Haile, Simon, McEwan, Iain J., Plymate, Stephen, Sadar, Marianne D.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5010454/
https://ncbi.nlm.nih.gov/pubmed/27140928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2901
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars